Gliclazide extended-release tablets can be replaced with glimepiride tablets, both belong to the sulfonylurea hypoglycemic drugs, but must be under the guidance of the physician, not blindly adjust the medication. Compared with gliclazide extended-release tablets, glimepiride has a more stabilizing effect on lowering sugar, is long-lasting and convenient, and can be taken once a day. Both are more effective for postprandial glucose elevation, but compared to gliclazide, glimepiride has glucose-dependent hypoglycemic effect, so the risk of hypoglycemia is lower and safer. However, it should be noted that the following groups of people are not recommended to take these two drugs. 1. Elderly people: Sulfonylurea hypoglycemic drugs have a higher risk of hypoglycemia compared to other types of drugs, and elderly diabetics are usually very prone to a combination of various cardiovascular and cerebrovascular diseases, and hypoglycemia may induce further aggravation of these diseases. 2. People with serious hypoglycemic events: people who have experienced hypoglycemic coma or have frequent hypoglycemic episodes are not recommended to take sulfonylurea hypoglycemic drugs. 3. Sulfonylurea hypoglycemic drugs are contraindicated in type 1 diabetes, breastfeeding, and gestational diabetes in women and children. If you feel unwell, consult a doctor promptly.